商品
发表于 2025-3-28 14:34:06
Outcome and Mortality in Renal Failure Related RLSth a high prevalence of depression and sleep disorders such as insomnia, excessive daytime sleepiness and movements disorders during sleep. Clinicians should make every effort to diagnose and treat symptoms of restless legs in this at-risk population.
Measured
发表于 2025-3-28 22:02:13
Managing Concurrent Medicationsent condition. It is also a disorder with a natural progression that can compound the effects of some concurrent medications. It is therefore, important to regularly review medications’ lists, to devise individual treatment plans and to alert the patients and the other providers to possible interactions.
发电机
发表于 2025-3-29 02:15:40
http://reply.papertrans.cn/83/8289/828828/828828_43.png
Truculent
发表于 2025-3-29 06:22:19
http://reply.papertrans.cn/83/8289/828828/828828_44.png
stratum-corneum
发表于 2025-3-29 10:54:09
Heart Rate and Blood Pressure Changes Associated with Periodic Limb Movementst also the autonomic function, cortical electroencephalographic (EEG) activities, the respiratory system, and several other functions too. This chapter will review the present data available to establish the complex relationship of PLMS with HR and BP.
典型
发表于 2025-3-29 11:32:07
http://reply.papertrans.cn/83/8289/828828/828828_46.png
不能根除
发表于 2025-3-29 18:23:54
Impulse Control Behavior in Movement Disorders: Focus on Restless Leg Syndrome explores the current state of knowledge regarding the phenotype, neurobiological basis, diagnosis, and management of these disorders focusing on RLS; a common sleep-related movement disorder characterized by relevant psychocognitive features.
JAUNT
发表于 2025-3-29 19:51:35
http://reply.papertrans.cn/83/8289/828828/828828_48.png
miscreant
发表于 2025-3-30 00:23:12
http://reply.papertrans.cn/83/8289/828828/828828_49.png
Gorilla
发表于 2025-3-30 06:47:39
Management of Augmentationger acting (rotigotine, cabergoline) dopamine-receptor agonists. However, it is unclear whether this finding is related to masking of earlier symptom onset by the longer acting dopaminergic agents, or whether this reflects a truly reduced risk of augmentation.